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Besides iatrogenic immunosuppression, endogenous
suppression by regulatory T cells (Tregs) may also mediate
inhibition of effector T cells after transplantation. Here we
determined the effect of common immunosuppressive drug
regimens on both Treg and effector T cells. Tregs and
cytomegalovirus (CMV)-specific T cells were quantified in 88
renal transplant recipients, 58 hemodialysis patients, and 22
controls. T cell dynamics were longitudinally assessed within
20 weeks after transplantation. The number of Tregs was
quantified by measurement of CD25 and/or FOXP3-positive
cells and by functional assays. CMV-specific T cells were
quantified by stimulation-induced intracellular cytokine
analysis. Treg frequencies in transplant recipients were
significantly lower compared to those in hemodialysis
patients and controls. These lower Treg levels were
associated with a less pronounced suppression of effector
function. Treg levels decreased within the first weeks after
transplantation and remained low in the long term. In
contrast, although decreased at early post-transplant,
long-term levels of CMV-specific T cells normalized to levels
found in hemodialysis patients and controls. These studies
suggest that there is an initial decrease of Tregs and effector
T cells as a consequence of a direct inhibitory effect of
immunosuppressive drugs. In the long term, persistently
low Treg levels may favor normalization of effector T cells
to ensure sufficient pathogen control.
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Transplantation tolerance is defined as a state of donor-
specific unresponsiveness, while preserving responsiveness
toward pathogens and third party antigens.1 Experimental
studies suggest that tolerance induction may involve clonal
deletion, T-cell anergy and active regulation by regulatory T
cells (Tregs).2 Among Tregs, the population of CD4 T cells
expressing highest levels of CD25 are best characterized. This
subset comprises approximately 5–10% of the total CD4
T-cell population and is involved in the maintenance of
tolerance toward self- and alloantigens.1,3 On the other hand,
Tregs have been shown to impair efficient control of tumors
or infectious pathogens, thereby contributing to the devel-
opment of malignant diseases and chronic infections.4–6
In recent years, Tregs were identified as promising cellular
correlate of tolerance in rare cases of operationally tolerant
transplant patients who showed long-term graft survival and
sufficient pathogen control in the absence of immunosup-
pressive drugs. Drug-free operationally tolerant liver trans-
plant recipients showed higher levels of CD4þCD25þ T
cells expressing FOXP3 as compared with a control group of
patients where drug-weaning was followed by acute rejec-
tion.7 Likewise, whereas clinically tolerant kidney transplant
recipients displayed normal levels of CD4þCD25þ T cells
and FOXP3 transcripts, respective levels were decreased in
patients with chronic rejection.8 On the basis of these
observations, an improved knowledge on the effect of
currently used immunosuppressive drugs on the homeostasis
of regulatory and effector T cells is essential for the
development of strategies toward manipulating regulatory
and effector T cells in humans.
Patients before and after transplantation represent ideal
candidates to study the dynamics of regulatory and effector T
cells in the presence of immunosuppressive drugs. We have
earlier shown that antigen-specific effector T-cell frequencies
decrease in the first months after transplantation.9 Interest-
ingly, however, long-term levels of specific T cells seem to
normalize and do not differ from those found in healthy
controls.9–11 This is surprising, as effector T cells remain
under influence of both ongoing iatrogenic immunosuppres-
sion as well as endogenous immunosuppression mediated by
Tregs. This study was carried out to characterize the impact
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of a common immunosuppressive drug regimen consisting of
daclizumab and/or steroids, azathioprine, and calcineurin
inhibitors on Treg levels in patients after renal transplanta-
tion. Moreover, using cytomegalovirus (CMV) as an example
for a clinically relevant persistent pathogen, we addressed,
whether the restoration of CMV-specific effector T-cell
responses in long-term transplant recipients was associated
with changes in Treg frequencies.
RESULTS
Low frequencies of functionally active CD4þCD25þ T cells
and normal effector T-cell frequencies in long-term transplant
recipients
To elucidate the effect of long-term immunosuppressive
treatment on Tregs and CD4þCD25þ T cells were cross-
sectionally quantified from whole blood of 88 long-term
renal transplant recipients using flow cytometry. Healthy
individuals (n¼ 22) as well as patients on hemodialysis
(n¼ 58) served as control groups. In a subset of controls,
hemodialysis patients and transplant recipients, high cell-
surface expression of CD25 on CD4 T cells (Figure 1a, upper
panel) was analyzed in combination with low expression of
CD127 (middle panel)12 and intracellular expression of the
Treg-specific transcription factor FOXP3 (lower panel). As
Treg frequencies determined by this panel of markers showed
a significant correlation with CD4þCD25þ T-cell frequen-
cies (Figure 1b, r2¼ 0.95, Po0.0001), CD4þCD25þ T-cell
frequencies were analyzed as a meaningful estimation of the
Treg repertoire in the large group analysis (Figure 1c).
Interestingly, transplant recipients showed significantly lower
frequencies of CD4þCD25þ T cells (4.36±1.52%, n¼ 88),
as compared with healthy controls (6.84±1.49%, n¼ 22,
Po0.0001, Figure 1c). Moreover, lower frequencies of
CD4þCD25þ T cells were not a direct effect of renal
insufficiency, as hemodialysis patients had CD4þCD25þ
T-cell levels similar to healthy controls (7.60±2.26%, n¼ 58;
Figure 1c). The immunosuppressive drug regimens applied
in our cohort of patients had no differential effect on
CD4þCD25þ T-cell levels, as results did not differ in
patients on cyclosporine A and tacrolimus or in patients who
did or did not receive daclizumab (Table 1).
To exclude the possibility that low frequencies of Tregs in
transplant recipients may result from an increase in absolute
numbers of CD4 T cells, absolute numbers of
CD4þCD25þ T cells were determined in the three groups.
In line with relative frequencies, absolute numbers of
CD4þCD25þ T cells in renal transplant recipients were
significantly lower (37.0±16.9/ml) as compared with respec-
tive numbers in controls (55.8±23.5/ml) and hemodialysis
patients (48.8±24.3/ml, Po0.0001). Together, these data
suggest that immunosuppressive drug therapy significantly
affects Treg frequencies in the long term.
A lower percentage of CD4þCD25þ T cells in transplant
recipients should result in a less pronounced increase in
effector T-cell reactivity upon depletion of regulatory cells.
To address the functionality of CD4þCD25þ T cells,
the percentage of interferon (IFN)-g and interleukin (IL)-2-
positive effector T cells was quantified after polyclonal 18-h
stimulation with Staphylococcus aureus Enterotoxin B in the
presence or absence of cells strongly positive for CD25
(Figure 2). CD4 T cells strongly expressing CD25 were
efficiently depleted from whole blood (Figure 2a and b, by
median percentages of 91.4 in patients and 91.0 in controls,
Figure 2c), whereas CD25 low CD4 T cells were unaffected
(Figure 2a and b). In line with Figure 1c, the group of
transplant recipients had lower baseline levels of
CD4þCD25þ T cells as compared with controls (Figure 2c,
4.19±0.60% vs 7.96±0.57; n¼ 9; P¼ 0.0003). In healthy
controls, this depletion led to a significant increase in IFN-g
and IL-2 producing CD4 T cells (2.1±1.8-fold and 1.6±0.9-
fold, respectively, Figure 2d and e). Interestingly, in line with
lower baseline frequencies of CD4þCD25þ T cells in
transplant recipients, the increase in IFN-g and IL-2
producing CD4 T cells after depletion was less pronounced
(1.5±0.5-fold and 1.2±0.2-fold, respectively, Figure 2d
and e) and did not even reach statistical significance for IL-
2-producing cells (P¼ 0.11, Figure 2e). Of note, basal T-cell
reactivity in non-depleted samples from transplant recipients
was not lower, as the percentage of reactive IFN-g-positive
CD4 T cells was 0.60±0.25% in controls and 1.29±0.94% in
transplant patients (P¼NS), and respective percentages of
IL-2-positive CD4 T cells were 1.23±0.67 and 2.65±1.82%,
respectively (P¼ 0.04). Thus, the less pronounced effect of
Treg depletion in transplant recipients is unlikely to be due to
drug-mediated hyporesponsiveness.
Together, these data indicate that CD4þCD25þ T cells
are functionally active and lower frequencies in transplant
recipients may result in a less pronounced suppression of
effector T cells. This may be relevant in vivo in that the
downmodulation of CD4þCD25þ T cells may contribute
to a compensation for a drug-related immunosuppressive
effect on protective T-cell immunity against infectious
pathogens. To address this hypothesis, effector T-cell
frequencies toward CMV, a common persistent pathogen,
were quantified in those hemodialysis patients and
renal transplant recipients that were seropositive for CMV.
CMV-specific CD4 T cells were quantified directly from
whole blood after a 6-h stimulation with CMV lysate
and were identified as the percentage of activated cells
expressing CD69 and IFN-g. Interestingly, despite
drug-mediated immunosuppression, there was indeed
no significant difference in median CMV-specific T-cell
frequencies in renal transplant recipients (2.5%, from 0.1 to
34.7%, n¼ 52, 7.0±5.5 years after transplantation) and
hemodialysis patients (4.3%, from 0.3 to 25.1%, n¼ 37,
P¼ 0.09; Figure 3). This also held true for larger cohorts of
CMV-seropositive hemodialysis and transplant patients
(data not shown).9,13 Although CMV-specific T cells were
not analyzed in the particular group of healthy individuals
shown in Figure 1c, median CMV-specific T-cell
levels in hemodialysis patients and renal transplant were
in the same range as respective frequencies in healthy
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controls described earlier using the same methodology
(approximately 2%).9,13
CD4þCD25þ T cells and CMV-specific effector T cells rapidly
drop after transplantation
To address the kinetics of regulatory and effector T cells after
onset of immunosuppression, CD4þCD25þ T cells and
CMV-specific CD4 T cells from 13 patients were analyzed
before as well as longitudinally within the first 20 weeks after
transplantation (Figure 4). Among them, 10 were seroposi-
tive for CMV. All patients received a calcineurin inhibitor-
based drug regimen and 5 doses of daclizumab during the
first 8 weeks after transplantation (as indicated by triangles in
Figure 4a). As shown in Figure 4a, CD4þCD25þ T-cell
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Figure 1 | Low frequencies of CD4þCD25þ T cells in long-term renal transplant recipients. (a) Representative dotplots of a flow
cytometric analysis of regulatory T cells (Tregs) in a healthy control, a hemodialysis patient, and a renal transplant recipient. Numbers
indicate percentages of CD4 T cells expressing high levels of CD25 alone (upper panel) or in combination with low levels of CD127 (middle
panel), or intracellular FOXP3 (lower panel). (b) Frequencies of Tregs determined by CD4 and high levels of CD25 show a significant
correlation with Treg frequencies defined by T cells expressing CD4, CD25, and FOXP3, and lacking expression of CD127 (r2¼ 0.95,
Po0.0001, shown are data from 15 healthy controls, 15 hemodialysis patients, and 15 renal transplant recipients). (c) CD4þCD25þ T-cell
frequencies in long-term renal transplant recipients (4.36±1.52% n¼ 88) are significantly lower as compared with respective T-cell
frequencies in hemodialysis patients (7.60±2.26%, n¼ 58) and healthy controls (6.84±1.49%, n¼ 22, P¼ 0.001). This significant difference
was also observed when Tregs were analyzed using the panel of CD4, CD25, FOXP3, and CD127 in a subgroup of controls (6.70±1.53%),
hemodialyis patients (8.85±2.73%), and renal transplant recipients (4.40±1.17%, Po0.0001).
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frequencies drop immediately after transplantation and remain
stable at the low level shown for long-term transplant reci-
pients (Figure 1c). Within the same time frame, CMV-specific
CD4 T cells showed a similar decline of more than 50%
(Figure 4b, n¼ 10 patients). Interestingly, however, unlike
Tregs, effector T-cell levels re-increased to pre-transplant levels
Table 1 | CD4+CD25+ T-cell levels of the study cohort
Renal Tx
Controls
n=22
Hemodialysis
n=58
Cyclosporine A (CyA)
n=56
Tacrolimus
n=32
ANOVA with Bonferroni’s post-test
Overall P-value: Po0.0001
4.12±0.18% 4.77±0.31% CyA vs tacrolimus, P40.05
CyA vs hemodialysis or vs controls, Po0.001
Tacrolimus vs hemodialysis or vs controls, Po0.001
Hemodialysis vs controls, P40.05
6.84±1.49% 7.60±2.26% Daclizumab
n= 30
No daclizumab
n= 58
Overall P-value: Po0.0001
4.84±0.31% 4.11±0.18% Daclizumab vs no daclizumab, P40.05
Daclizumab vs hemodialysis or vs controls, Po0.001
No daclizumab vs hemodialysis or controls, Po0.001
Hemodialysis vs controls, P40.05
Levels of CD4+CD25 + T cells in transplant recipients are significantly lower as compared with those in controls or hemodialysis patients.
This is irrespective of the immunosuppressive drug regimen.
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Figure 2 |CD4þCD25þ T cells have suppressive activity on effector CD4 T cells. (a) CD25-antibody-mediated depletion using anti-
CD25-coupled dynabeads affects CD4 T cells expressing high levels of CD25, whereas CD25-low and CD25-negative CD4 T cells are
unaffected. Representative dotplots of CD4 T cells of a healthy control and a renal transplant recipient in non-depleted (left) and depleted
samples. CD4 T cells expressing high and low levels of CD4 as well as CD25-negative CD4 T cells are indicated and (b) mean percentages of
CD4þCD25-high, CD4þCD25-low, and CD4þCD25-negative T cells were quantified in non-depleted and depleted samples from nine
controls and nine renal transplant recipients. The bar denotes the s.d. (c) CD4þCD25þ cells were efficiently depleted from whole blood of
healthy controls and transplant recipients. Depleted and non-depleted blood samples were stimulated for 18 h using S. aureus Enterotoxin B
and analyzed for the induction of IFN-g (d) and IL-2 (e). The percentage of cytokine-positive CD4 T cells in each group was set to ‘1’ and the
fold change in depleted reactions was quantified as compared with non-depleted samples.
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in the six patients who were available beyond 1 year of
transplantation (median frequencies of 2.80% before trans-
plantation, 2.38% after 12 months, P40.05, data not shown,
see also Figure 3).
The decrease of Tregs after transplantation is a combined
effect of immunosuppressive drugs
Treatment with the monoclonal anti-CD25 antibody dacli-
zumab was shown earlier to induce internalization of
CD25.14 To exclude the possibility that the rapid decrease
in CD4þCD25þ T cells could be a mere consequence of
CD25 downmodulation without affecting the actual levels of
Tregs intracellular FOXP3 was used as an established marker
to quantify Tregs independent of CD25 (Figure 5). First, the
immediate effect of daclizumab on Treg frequencies was
analyzed in vitro after the incubation of peripheral blood
mononuclear cells from three healthy individuals with and
without daclizumab. Representative profiles of a double
staining of CD4 T cells with CD25 and FOXP3 are shown in
Figure 5a. Of note, CD25 expression was analyzed by an
antibody clone that is not competing with the epitope of
daclizumab. As summarized in Figure 5b, daclizumab led to a
rapid drug-induced downmodulation of CD25. This, how-
ever, was not associated with a physical depletion of Tregs, as
detection of FOXP3-positive cells was unaffected by daclizu-
mab treatment in vitro (Figure 5c). To address the effect of a
daclizumab-based drug regimen on FOXP3þ Treg frequen-
cies in vivo, CD4þCD25þ and CD4þ FOXP3þ T cells
were longitudinally analyzed in five renal transplant recipi-
ents receiving daclizumab before and during the first 8 weeks
after transplantation (Figure 5d and e). In line with results
shown in Figures 4a and 5b, a rapid loss in detectability
of CD4þCD25þ T cells was observed (Figure 5d).
Likewise, although declining less rapidly, CD4þ FOXP3þ
T cells showed a continuous decrease toward low levels
observed for long-term transplant recipients (Figure 5e).
If the long-term decrease in Treg frequencies observed in
Figure 1c were an exclusive effect of daclizumab, patients
who had received daclizumab in the first weeks after
transplantation should have lower Treg frequencies as
compared with patients on a daclizumab-free regimen. This,
however, was not the case, as long-term Treg levels in
daclizumab-treated patients were not significantly different as
compared with patients without daclizumab treatment
(4.84±0.31 vs 4.11±0.18% in patients with and without
daclizumab, respectively, Table 1). Thus, the long-term
decrease of Tregs in our cohort is not an exclusive effect of
daclizumab but may instead result from the combined action
of immunosuppressive drugs.
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Figure 3 |No difference in CMV-specific CD4 T-cell frequencies
in hemodialysis patients and long-term renal transplant
recipients. CMV-specific T cells from CMV-seropositive individuals
were quantified after specific stimulation with CMV-lysate. CMV-
seronegative individuals did not show any CMV-specific T cells
(data not shown). CMV-specific CD4 T cells were identified as the
percentage of cells expressing CD69 and intracellular IFN-g.
Median frequencies in hemodialysis patients (4.3%, from 0.3 to
25.1%, n¼ 37) and renal transplant recipients (2.5%, from 0.1 to
34.7%, n¼ 52) did not differ (P¼ 0.09). Solid lines represent
medians. When CMV-specific CD4 T-cell frequencies were
stratified according to immunosuppression as in Table 1, there
were no significant differences either (data not shown).
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Figure 4 |Rapid drop of CD4þCD25þ T cells and CMV-
specific CD4 T cells after transplantation. (a) Levels of
CD4þCD25þ T cells drop immediately after transplantation and
remain stable at a lower level. CD4þCD25þ T cells from 13
patients were analyzed longitudinally before and within the first
20 weeks after transplantation. (b) Among those patients, 10 were
CMV-seropositive and were analyzed for CMV-specific CD4 T cells
that show a similar decline. The curve is calculated from
logarithmic numbers of CMV-specific CD4 T cells (right axis). The
corresponding percentages of cells are shown on the left axis. As
expected, CMV-specific CD4 T-cell levels beyond 1 year after
transplantation (n¼ 5 patients were available) were
indistinguishable from pre-transplant values (P40.05, data not
shown). Values represent means±s.e. of the mean. Black triangles
depict time points of daclizumab infusion. Of note, the epitope of
the anti-CD25 antibody used for flow cytometric analysis differs
from and does not compete with the epitope of daclizumab. Thus,
the rapid drop in CD4þCD25þ T cells cannot be explained by
masking of the anti-CD25 epitope by daclizumab.
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Figure 5 |Daclizumab treatment in vitro leads to a downregulation of CD25 without affecting levels of FOXP3þ CD4 T cells. (a) Flow
cytometric analysis of CD25 cell-surface expression and intracellular FOXP3 in CD4 T cells in peripheral blood mononuclear cells (PBMC)
treated without (upper panel) and with 20mg/ml daclizumab (lower panel). CD4þCD25þ T cells (b) and CD4þ FOXP3þ T cells (c) were
analyzed at the time points indicated. Results from three individuals are shown (mean±s.e. of the mean). The effect of five doses of
daclizumab was analyzed in five patients receiving an immunosuppressive drug regimen consisting of tacrolimus, azathioprine, and
steroids. CD4 T cells expressing high levels of CD25 (d) or intracellular FOXP3 (e) were quantified during the first 8 weeks. Curves
representing values for each patient and mean±s.e. are shown.
562 Kidney International (2009) 76, 557–566
or ig ina l a r t i c l e D Presser et al.: Dynamics of regulatory and effector T cells
DISCUSSION
The induction of transplantation tolerance with preserved
pathogen-specific immunity represents an ultimate goal
toward achieving stable graft function in the absence of
immunosuppressive drugs. Animal models have convincingly
shown that alloreactive T cells may be modulated by a subset
of T cells with regulatory function,15 that not only inhibited
graft rejection but also led to the induction of tolerance.16
This has stimulated extensive research as to whether Tregs
may similarly be induced to confer a state of transplantation
tolerance in humans. Here we show that a common
immunosuppressive drug regimen consisting of daclizumab
and/or steroids, azathioprine, and calcineurin inhibitors leads
to a profound long-term decrease of Tregs. Although the state
of tolerance is a complex process that involves both T-cell
deletion, anergy and Tregs,2 these data suggest that this
immunosuppressive drug regimen may represent a potent
barrier toward Treg-mediated tolerance. On the other hand,
however, functional assays and the differential behavior of
effector and Tregs after tapering of immunosuppression
indicate that low levels of Tregs may favor the normalization
of pathogen-specific effector T-cell frequencies toward levels
observed in immunocompetent controls. Thus, we show for
the first time that the decrease in Tregs may be beneficial and
important to maintain specific immunity against infectious
pathogens.
Although our data do not allow drawing firm conclusions
about a causal link between the dynamics of regulatory and
effector T cells, there is evidence from both animal models
and humans that kinetics are related. The particular
importance of a decrease in Tregs on pathogen-specific
effector T cells for the transplant recipient in vivo is
supported by our findings of a less pronounced suppression
of effector T-cell function in transplant recipients and by
animal models showing that memory responses toward
herpes simplex virus type 1 developed better if Tregs were
absent at the time of infection. Moreover, recall responses
were higher if Tregs were removed before antigen re-
exposure.17,18 Likewise, in human hepatitis C infection, low
levels of Tregs have been associated with a better resolution of
infection as compared with patients with chronic viral
replication.5
The elucidation of the individual contribution of a single
drug in modulating Treg levels is difficult to achieve in a
clinical setting where patients routinely receive an immuno-
suppressive combination therapy. Animal models, however,
have shown that IL-2 has a major role in both generating and
maintaining Tregs,19,20 and knock-out mice for IL-2 or IL-2
receptor-b die of autoimmunity. Interestingly, this auto-
immunity may be prevented by the administration of
Tregs.21–23 Moreover, the role of IL-2 as survival factor for
Tregs was recently supported in pediatric patients with
sarcoma, where the administration of IL-2 led to a profound
increase in Tregs as compared with patients without IL-2
therapy.24 Given that both calcineurin inhibitors and
daclizumab are known to interfere with IL-2 formation and
signaling, respectively,14,25,26 it is conceivable, that these
drugs may well affect Treg levels and their function in the
long-term.27–29 We used a combination of FOXP3, CD127
and/or high levels of CD25 as an established panel of markers
to identify Tregs. Although Treg levels may to some extent be
overestimated due to the fact that both CD25 as well as
FOXP3 may also be upregulated on activated T cells,30,31 this
effect is unlikely to have any confounding impact on our
findings in transplant recipients, where we observe a general
drop in Treg levels. In line with low Treg levels in
transplant recipients, functional assays after depletion of
CD25high cells was associated with a less pronounced increase
in effector function of remaining T cells as compared with
controls. We have preliminary evidence that Tregs in
hemodialysis patients may be functionally impaired despite
normal levels (unpublished observations). Thus, one cannot
exclude that the less pronounced increase in T-cell effector
function upon depletion of Tregs in transplant recipients may
result from both a low number and a functional deficiency of
Tregs. Our findings of low numbers of Tregs are also in line
with recent reports that cross-sectionally showed low
frequencies of CD4þCD25þ T cells in transplant recipients
receiving calcineurin inhibitors.32,33 We now addressed the
kinetics of this decrease in patients receiving both calcineurin
inhibitors and five doses of daclizumab and found that
CD4þCD25þ T-cell levels showed a more than 50%
decline already within 1 week. As suggested from CD25-
independent co-staining using FOXP3, this rapid initial
decline was most attributable to a downmodulation of the
CD25 molecule, as levels of FOXP3þ T cells were reduced
less rapidly (Figure 5). In line with this evidence, short-term
treatment with daclizumab in vitro led to a rapid loss of
CD25 expression without physically depleting FOXP3þ T
cells. Nevertheless, within 8 weeks after transplantation, even
FOXP3þ T cells showed a continuous decline toward low
Treg levels observed in long-term transplant recipients, an
effect most probably due to the combined effect of
immunosuppressive drugs.
The decline of Tregs after daclizumab treatment in
patients on a calcineurin inhibitor-based drug regimen is in
line with studies in patients receiving basiliximab in com-
bination with cyclosporine A.33,34 Those data seem to con-
trast with the recent finding that an induction therapy with
a single dose of daclizumab did not affect CD4þCD25þ
T-cell levels in the long term.35 However, these patients only
received one dose of daclizumab and were concomitantly
treated using a rapamycin-based drug regimen. Thus far,
rapamycin is the only immunosuppressive drug that appears
to be associated with a preservation of Tregs both in animals
and humans.32,36,37 As opposed to a cyclosporine A-based
regimen, rapamycin has also been shown to more strongly
and rapidly induce a homeostatic expansion of regulatory
cells in renal transplant recipients after induction therapy
with the T-cell depleting antibody Campath-1H.38
Downmodulation of peripheral Treg frequencies is a
particular feature of drug-mediated immunosuppression,
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as respective T-cell levels in hemodialysis patients with
uremic immunodeficiency (Figure 1c) or in HIV-infected
individuals39 were not lower than those in healthy controls.
The drop in Tregs within the first months after transplanta-
tion may result from a direct inhibitory effect of immuno-
suppressive drugs on the maintenance and/or development of
Tregs. This loss was also found for CMV-specific effector T
cells that show a similar decrease within the first months after
transplantation, thereby contributing to an increased in-
cidence of infectious complications (Figure 4b).9 Interest-
ingly, however, when tapering immunosuppression, virus-
specific T cells re-increase to reach pre-transplant levels
(Figure 3),9,13, whereas Treg levels remain low in the long
term. Thus, in addition to a mere drug action, the persistent
downmodulation of Tregs may be an indirect effect that
counteracts an overt drug-mediated suppression on effector
T cells. Thus, similar to animal models,17,18 low Treg levels
may help to re-reach a balanced equilibrium of specific
effector T-cell immunity needed to control persistently
replicating viral and bacterial pathogens in the long term.
In summary, this study shows that functionally active,
FOXP3-positive Tregs in patients receiving a calcineurin
inhibitor-based drug regimen rapidly decrease within the first
weeks after transplantation and remain low in the long term,
whereas CMV-specific effector T cells normalize to levels
found before transplantation or in immunocompetent
individuals. The increasing knowledge in Treg manipulation
will contribute to further progress in our understanding of
Treg biology and pathology and in clinical applications of
Tregs to control and manipulate immune responses toward
both alloantigens and infectious pathogens for the benefit of
the host.
MATERIALS AND METHODS
Patients
The study was conducted among 88 long-term renal transplant
recipients in our outpatient clinic (55.1±14.5 years; 7.6±6.2 years
after transplantation), 58 patients on hemodialysis (66.3±15.3
years; 3.0±2.2 years on hemodialysis; range 0.50–8.69 years), and 22
healthy controls (54.5±14.5 years). All transplant recipients had
stable graft function. All patients were transplanted or on
hemodialysis for at least 6 months, and had no signs or symptoms
of active infections during the study period. At the time of
transplantation, patients had received an immunosuppressive
therapy consisting of methylprednisolone (n¼ 88), azathioprine
(n¼ 88), and either cyclosporine A (n¼ 56) or tacrolimus (n¼ 32).
Among them, 30 patients had received induction therapy with five
doses of daclizumab (1mg/kg of body weight) given on day 0 and
after 2, 4, 6, and 8 weeks (see also Table 1). At the time of analysis,
patients were on an immunosuppressive maintenance drug regimen
(intended drug dosages are shown in brackets) consisting of either
cyclosporine A (n¼ 49, 100–150 ng/ml) or tacrolimus (n¼ 38,
5–10 ng/ml) and/or methylprednisolone alone (n¼ 77, 4mg/day)
or combined with azathioprine (n¼ 17, 50–150mg/day). Another
group of 13 patients (57.1±8.8 years of age) was followed
longitudinally before as well as during the first 20 weeks after
transplantation. Among them, 10 were seropositive for CMV. They
received an immunosuppressive drug regimen consisting of
daclizumab (n¼ 13), tacrolimus (n¼ 10) or cyclosporine A
(n¼ 3) and steroids alone (n¼ 2) or in combination with
azathioprine (n¼ 9) or mycophenolate mofetile (n¼ 2). Evidence
for CMV reactivation in CMV-seropositive patients was monitored
using a preemptive therapy regimen during the first 4 months after
transplantation. Functional assays were performed from nine
healthy individuals (40.3±7.5 years of age) and nine renal
transplant patients (55.2±9.1 years of age, 6.2±7.2 years after
transplantation). Blood was drawn in the morning before the intake
of immunosuppressive drugs. The study was performed in
adherence to the declaration of Helsinki and was approved by the
local ethics committee. All individuals gave informed consent.
Quantitation of Tregs within whole blood
Flow cytometric analysis of Tregs was performed on EDTA
anticoagulated peripheral whole blood. Cells were stained for
30min in the dark at room temperature using monoclonal
antibodies against CD4 (clone SK3) and CD25 (clone MA-251; all
from BD-Biosciences, Heidelberg, Germany). Thereafter, erythro-
cytes were lysed and leukocytes fixed using FACS (fluorescence-
activated cell sorting) lysing solution (BD-Biosciences) according to
the manufacturer’s instruction. FOXP3 expression was analyzed
from peripheral blood mononuclear cells after cell surface staining
with anti-CD4-FITC (clone 13B8.2; Beckman Coulter, Krefeld,
Germany) and anti-CD25 (clone MA-251). Intracellular co-staining
with anti-FOXP3 (clone PCH101) was performed using a FOXP3
staining kit (eBiosciences, San Diego, CA, USA) according to the
manufacturer’s instruction. Subsequently 20.000 CD4 T cells were
analyzed on a FACS-Calibur cytometer using CellQuest Pro-4.0.2
(BD-Biosciences). Where indicated, Tregs were stained using CD4
PerCP, CD25 PE, FOXP3 APC, and CD127 FITC (clone eBioRDR5,
eBiosciences). Absolute cell counts were determined by the use of
differential blood counts. To study the effect of daclizumab in vitro,
peripheral blood mononuclear cells from three healthy individ-
uals were pre-incubated with and without 20 mg/ml daclizumab
(Zenapax, Roche Pharma, Grenzach, Germany) at 41C for 1 h.
Thereafter, cells were incubated at 1 106 peripheral blood mono-
nuclear cells/ml and CD25 and FOXP3 expression was analyzed
before daclizumab treatment and at the time points indicated.
Quantitation of CMV-specific T cells
Titered amounts of CMV antigen and control antigen (32 ml/ml;
Virion, Wu¨rzburg, Germany) were used as stimulus in the presence
of 1 mg/ml anti-CD28 and anti-CD49d (clones L293 and 9F10; BD-
Biosciences) to induce antigen-specific activation and cytokine
induction. Stimulation and staining was carried out as described
before.9,13,40 Briefly, cells were incubated in 15ml-polypropylene
tubes at 371C at 6% CO2 for a total of 6 h. During the last 4 h 10mg/ml
of brefeldin A (Sigma, Deisenhofen, Germany) was added to block
secretion of cytokines. Thereafter, the blood was treated with 2mM
EDTA for 15min. Subsequently, erythrocytes were lysed and
leukocytes were fixed for 10min using BD lysing solution (BD-
Biosciences). Cells were washed once with FACS buffer (phosphate-
buffered saline, 5% fetal calf serum, 0.5% bovine serum albumin,
0.07% NaN3) and immunostained in FACS buffer containing 0.07%
saponin (Sigma) using anti-CD4 (clone SK3), anti-IFN-g (clone
4S.B3), anti-CD69 (clone L78; all from BD-Biosciences). At least
15.000 CD4 T cells were analyzed. The percentage of specific T cells
was calculated by subtracting the frequency obtained by the
respective control stimulation. The lower limit of detection is
0.05% as established earlier.9
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Functional analysis of CD4þCD25þ positive T cells
CD25-positive cells were depleted directly from heparinized whole
blood using anti-CD25-conjugated dynabeads (Invitrogen,
Karlsruhe, Germany). To largely eliminate soluble CD25 from
plasma, whole blood was washed three times with 6.5 volumes of
RPMI and resuspended in 2 volumes of RMPI-0.5% human serum
albumine. A volume of 1200ml of blood suspension was incubated
under gentle agitation in 15-ml polypropylene tubes with 30ml of
equilibrated anti-CD25-conjugated dynabeads at 41C. After 45min,
a cylindric magnet (5mm diameter, 2mm height, www.supermag-
nete.de) was fixed to the tube using adhesive tapes and incubated for
10min at a 301 slant at 41C. Cell suspension was pipetted off, and
the depletion procedure was repeated once. The same volume of
blood was mock-treated. Both fractions were stained as described
above to analyze depletion efficiency. Polyclonal stimulation of
600ml depleted and non-depleted cell suspension, respectively, was
carried out using 2.5 mg/ml S. aureus Enterotoxin B (Sigma) for 18 h
in the presence of 10% fetal calf serum. During the last 4 h, brefeldin
A was added, Thereafter, cells were fixed and stained as described
above using anti-IL-2 (clone MQ1-17H12), anti-CD4, anti-CD69,
and anti-IFN-g.
Statistical analysis
Statistical analysis was performed using Prism V4.03 software
(Graphpad, San Diego, CA, USA). Correlation between high CD25
cell-surface expression and the combination of high CD25 cell-surface
expression, intracellular FOXP3 expression, and low expression of
CD127 was calculated according to Pearson. The analysis of variance
test with Bonferroni’s post-test was used to calculate differences in
Treg frequencies among renal transplant recipients, hemodialysis
patients, and immunocompetent individuals. The paired t-test was
used for functional assays in the presence or absence of Tregs. The
Mann–Whitney test was applied to compare CMV-specific CD4
T-cell frequencies in hemodialysis patients and renal transplant
recipients.
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